NASDAQ
KMDA

Kamada

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

Kamada Stock Price

Vitals

Today's Low:
$5.14
Today's High:
$5.25
Open Price:
$5.25
52W Low:
$3.72
52W High:
$5.85
Prev. Close:
$5.31
Volume:
19754

Company Statistics

Market Cap.:
$305.19 million
Book Value:
3.902
Revenue TTM:
$145.81 million
Operating Margin TTM:
6.52%
Gross Profit TTM:
$46.70 million
Profit Margin:
2.35%
Return on Assets TTM:
1.92%
Return on Equity TTM:
1.97%

Company Profile

Kamada had its IPO on 2013-05-31 under the ticker symbol KMDA.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Kamada has a staff strength of 380 employees.

Stock update

Shares of Kamada opened at $5.25 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $5.14 - $5.25, and closed at $5.14.

This is a -3.2% slip from the previous day's closing price.

A total volume of 19,754 shares were traded at the close of the day’s session.

In the last one week, shares of Kamada have slipped by -10.76%.

Kamada's Key Ratios

Kamada has a market cap of $305.19 million, indicating a price to book ratio of 1.1242 and a price to sales ratio of 1.5766.

In the last 12-months Kamada’s revenue was $145.81 million with a gross profit of $46.70 million and an EBITDA of $20.87 million. The EBITDA ratio measures Kamada's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Kamada’s operating margin was 6.52% while its return on assets stood at 1.92% with a return of equity of 1.97%.

In Q2, Kamada’s quarterly earnings growth was a negative -74.9% while revenue growth was a positive 58.7%.

Kamada’s PE and PEG Ratio

Forward PE
10.3306
Trailing PE
66.375
PEG
8.75

Its diluted EPS in the last 12-months stands at $0.08 per share while it has a forward price to earnings multiple of 10.3306 and a PEG multiple of 8.75. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Kamada’s profitability.

Kamada stock is trading at a EV to sales ratio of 1.6038 and a EV to EBITDA ratio of 62.6592. Its price to sales ratio in the trailing 12-months stood at 1.5766.

Kamada stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$314.39 million
Total Liabilities
$65.83 million
Operating Cash Flow
$0
Capital Expenditure
$1.05 million
Dividend Payout Ratio
0%

Kamada ended 2024 with $314.39 million in total assets and $0 in total liabilities. Its intangible assets were valued at $314.39 million while shareholder equity stood at $176.75 million.

Kamada ended 2024 with $0 in deferred long-term liabilities, $65.83 million in other current liabilities, 11737000.00 in common stock, $-48481000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $21.79 million and cash and short-term investments were $21.79 million. The company’s total short-term debt was $5,507,000 while long-term debt stood at $10.74 million.

Kamada’s total current assets stands at $129.68 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $27.66 million compared to accounts payable of $27.97 million and inventory worth $80.24 million.

In 2024, Kamada's operating cash flow was $0 while its capital expenditure stood at $1.05 million.

Comparatively, Kamada paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$5.14
52-Week High
$5.85
52-Week Low
$3.72
Analyst Target Price
$12.5

Kamada stock is currently trading at $5.14 per share. It touched a 52-week high of $5.85 and a 52-week low of $5.85. Analysts tracking the stock have a 12-month average target price of $12.5.

Its 50-day moving average was $5.24 and 200-day moving average was $4.79 The short ratio stood at 2.37 indicating a short percent outstanding of 0%.

Around 1380.7% of the company’s stock are held by insiders while 3475.9% are held by institutions.

Frequently Asked Questions About Kamada

The stock symbol (also called stock or share ticker) of Kamada is KMDA

The IPO of Kamada took place on 2013-05-31

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
$13.07
-0.03
-0.23%
Anjani Foods Ltd (ANJANIFOODS)
$30.13
-0.35
-1.15%
$195.8
-15.05
-7.14%
$0.02
0.01
+28.95%
Adroit Infotech Ltd (ADROITINFO)
$27.07
0.42
+1.58%
$501.25
-39.75
-7.35%
$11.79
-0.11
-0.91%
$1042.55
-35.1
-3.26%
KonaTel Inc (KTEL)
$0.8
-0.01
-1.11%
$4.3
0.11
+2.63%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. It has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. Kamada Ltd. was incorporated in 1990 and is headquartered in Rehovot, Israel.

Address

2 Holzman Street, Rehovot, Israel, 7670402